

**CERTIFICATE OF A PHARMACEUTICAL PRODUCT<sup>1</sup>**

No of Certificate : 4276091/TS/2024

Valid UpTo: **14/05/2026**

1.Name and Dosage form of Product:

Exporting(Certifying)Country: **INDIA**

**Bedaquiline Tablets 100 mg Each Uncoated Tablet Contains Bedaquiline Fumarate Equivalent to Bedaquiline ----- 100 mg**

1.1 Active Ingredients(s)<sup>2</sup> and amount(s) per unit dose<sup>3</sup>:

Importing(Requesting) country **Cambodia**

Active ingredients and amount per unit dose: Bedaquiline Fumarate IH 120.890 mg For complete composition including excipients, see attached: Lactose monohydrate (Sheffield SD Fastflo 316) Ph. Eur 143.000 mg, Maize Starch (Maize Starch B) Ph. Eur 65.000 mg, Hydroxypropyl MethylCellulose (Methocel E 5 Premium LV) Ph. Eur 9.000 mg, Polysorbate (Tween 80) Ph. Eur 1.000 mg, Purified Water Ph. Eur Q.S, Microcrystalline Cellulose (Avicel PH 102) Ph. Eur 84.110 mg, Croscarmellose Sodium (Ac-Di-Sol) Ph. Eur 20.000 mg, Colloidal Silicon Dioxide (HDK N 20) Ph. Eur 2.500 mg, Magnesium Stearate (Ligamed -MF-2V) Ph. Eur 4.500 mg.

For complete qualitative composition including excipients see above<sup>4</sup>

1.2 Is this Product licensed to be placed on the market for use in Exporting country?<sup>5</sup>

**Yes**

1.3 Is this product actually on the marketing in the Exporting Country?

**Yes**

If the answer to 1.2 is Yes, continue with section 2A and omit section 2B.If the answer to 1.2 is No, omit section 2A continue with section 2B<sup>6</sup>

2A.1 Number of Product Licence<sup>7</sup>: " **L.Dis.No.1746935/TS/2021 S No: 1 Dated: 30/09/2021**"

2A.2 Product License Holder(Name and address): M/s MSN LABORATORIES PRIVATE LIMITED, Formulation Division, Unit-II, Sy. No.1277 & 1319 to 1324, Nandigama Village , Nandigama Mandal , Ranga Reddy District Pincode 509228, Telangana State, India.

2A.3 Status of License Holders<sup>8</sup> : a

2A.3.1 For Category b and c the name and address of the manufacturer producing the dosage form is <sup>9</sup> na

2A.4 Is Summary basis of approval appended ? <sup>10</sup> No

2A.5 Is the Attached, officially approved production information complete and consonant with the license?<sup>11</sup>: Not Provided

2A.6 Applicant for Certificate, if different from licence holder (name and address) na

2B.1 Applicant for Certificate(Name and Address)

2B.2 Status of Applicant<sup>8</sup>

2B2.1 For Categories (b) and (c) the name and address of the manufacturer producing the dosage form is<sup>9</sup>

2B.3 Why is marketing authorisation lacking?

2B.4 Remarks<sup>13</sup> :

3 Does the certifying authority arrange for periodic section of the manufacturing plant in which the dosage form is produced?<sup>14</sup>

**Yes**

3.1 Periodicity of routine inspection(years)

**Once in a Year**

3.2 Has the Manufacture of this type of dosage form been inspected?

**Yes**

3.3 Do the facilities and operations conform to GMP as recommended by World Health Organization?<sup>15</sup>

**Yes**

4.0 Does the information Submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product?<sup>16</sup>

**Yes**

Address of Certifying Authority.

Drugs Control Administration, Vengalraonagar, Hyderabad500038, India  
Telephone No : 91-040-23814119 Fax No :91-040-23814360

Name of the authorized person:

Digitally Signed By

**B SOWBHAGYA JAXMI**

**Deputy Director and Certifying Authority**

**DRUGS CONTROL ADMINISTRATION**

**TELANGANA STATE**

Date:11-03-2024 17:30:02 PM

This certificate conforms to the format recommended by the World Health Organization  
(General instructions and explanatory notes overleaf)